MAPT and Alzheimer disease: In the present study, we sought to develop an algorithm using plasma Aβ1–42, Aβ1–40, tau, and APOE genotypes as a pre-screening tool to enhance the accuracy of predicting amyloid PET+ in clinically suspected mild cognitive impairment (MCI) and mild AD patients.